Harry M. Jansen Kraemer, Jr. is an executive partner with Madison Dearborn Partners, a private equity firm based in Chicago, Illinois and a Clinical Professor of Strategy at Northwestern University’s Kellogg School of Management. He was named the 2008 Kellogg School Professor of the Year. Harry is the author of two bestselling leadership books: “From Values to Action: The Four Principles of Values-Based Leadership” and “Becoming The Best: Build a World-Class Organization Through Values-Based Leadership”.
He is the former chairman and chief executive officer of Baxter International Inc., a $12 billion global healthcare company. He became Baxter’s chief executive officer in January 1999, and assumed the additional responsibility of chairman of Baxter’s board of directors in January 2000.
Mr. Kraemer joined Baxter in 1982 as director of corporate development. His twenty three year career at Baxter included senior positions in both domestic and international operations. In 1993, he was named senior vice president and chief financial officer, responsible for financial operations, business development, global communications, and European operations. Over the next several years, he assumed additional responsibility for Baxter’s Renal and Medication Delivery businesses. He was elected to Baxter’s board of directors in 1995, and was named president of Baxter International Inc. in 1997.
Before joining Baxter, Mr. Kraemer worked for Bank of America in corporate banking and for Northwest Industries in planning and business development.
Mr. Kraemer is active in business, education and civic affairs. He serves on the board of directors of Leidos Corporation, Sirona Dental Systems, Sage Products Inc., and Catamaran Corporation and on the board of trustees of Northwestern University, The Conference Board, NorthShore University Healthsystem and the Archdiocese of Chicago Finance Committee and School Board.
He is a member of the Dean’s Global Advisory Board of Northwestern University’s Kellogg School of Management. He is a member of the Commercial Club of Chicago, the Chicago Council on Global Affairs, and the Economics Club of Chicago. He is a past member of the Business Roundtable, the Business Council, and the Healthcare Leadership Council.
Mr. Kraemer graduated summa cum laude from Lawrence University of Wisconsin in 1977 with a bachelor’s degree in mathematics and economics. He received an MBA degree in finance and accounting from Northwestern University’s Kellogg School of Management in 1979 and is a certified public accountant. For his outstanding leadership and service, he received the 1996 Schaffner Award from the Kellogg School of Management. Harry enjoys jogging, tennis, skiing and reading, especially world civilization. Harry, his wife Julie, and their five children live in Wilmette, Illinois. More info on Harry at www.harrykraemer.org .
Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.
Recently, a clinical investigation on which Dr. Stock served as principal investigator led the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients.
Highly respected by his peers, Dr. Stock was named to the list of U.S. News “Top Doctors,” which denotes the top 10% of physicians within a region practicing a given specialty. He is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies. Dr. Stock specializes in liver, kidney and pancreas transplantation.
Peter G. Stock, M.D., Ph.D.
W. Ed Tyler
An experienced executive, Ed Tyler brings a long track record in leadership and entrepreneurial positions to his role. Mr. Tyler served as Chairman of the Board of First Industrial from January 2009 to January 2016. He also served as Lead Director and Interim CEO of First Industrial from October 2008 through January 2009.
Mr. Tyler is CEO of Ideapoint Ventures, an early stage venture fund that focuses on nanotechnologies.
Prior to joining Ideapoint, Mr. Tyler served as President and CEO of Moore Corporation Limited, a provider of data capture, information design, marketing services, digital communications and print solutions. During his tenure at Moore, he led a worldwide repositioning and restructuring of the company.
Earlier, Mr. Tyler worked for 24 years with R. R. Donnelley & Sons Company in Chicago, beginning his career as an electronics engineer and ultimately serving as Executive Vice President, Sector President, and 50 Chief Technology Officer. He also was responsible for 77 Capital, an early stage venture capital subsidiary of Donnelley, where he was directly responsible for investment decisions and worked closely with the portfolio companies while participating on many of their boards.
Mr. Tyler is a director of Nanophase Technologies Corporation (NASDAQ: NANX). He is a former Chairman of the American Red Cross (Mid-America Chapter) and Campaign Chairman of the United Way of Lake County, and serves as a director for several small, private companies. Mr. Tyler is a member of the Board of Directors of Lake Forest Graduate School of Management, where he is also an adjunct faculty member.
Dr. Zhang is currently the Professor of Anatomy and Neurology at the University of Wisconsin–Madison. He is also current the Group Coordinator for the Molecular and Genetic Sciences Group at the Waisman Center in Madison, Wisconsin. The Waisman Center is dedicated to the advancement of knowledge about human development, developmental disabilities, and neurodegenerative diseases throughout the lifespan. The center is one of 15 national facilities that includes a Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center and a University Center for Excellence in Developmental Disabilities. Zhang obtained his M.D. from the Wenzhou Medical College, Wenzhou, and PhD from the University of Saskatchewan, Canada.
Su-Chun Zhang, MD, PhD:
Dr. Alan Lewis currently serves as an advisor to biotech companies. He has served as President, CEO and Director of Ambit Biosciences, a privately held biotech company. He has also served as President and CEO of the Juvenile Diabetes Research Foundation (JDRF) and Novocell (ViaCyte). Prior to joining
Novocell, he was President of Celgene’s Signal Research, a wholly owned subsidiary of the Celgene Corporation. He was President, CEO and Director of Signal Pharmaceuticals, where he guided the company to its successful acquisition by Celgene. He previously was Vice President of Research at Wyeth. Dr. Lewis completed a postdoctoral fellowship at Yale University after obtaining a PhD in pharmacology from the University of Wales in Cardiff. Dr. Lewis serves as a director on the boards of Biomarin, Ctyochroma and Biotica.
Alan Lewis, PhD
Tommy G. Thompson
Tommy Thompson is a special advisor to RMS. Previously, as secretary of health and human services, Mr. Thompson was the nation’s leading advocate for the health and welfare of all Americans. In this role, Thompson launched major initiatives to urge all Americans to prevent disease by focusing on critical health areas such as obesity, diabetes, and health disparities. Thompson served as governor of Wisconsin, making state history when he was re-elected to office for a third term in 1994 and a fourth term in 1998. During his 14 years as governor, Thompson focused on revitalizing Wisconsin’s economy. He also gained national attention for his leadership on welfare reform, expanded access to healthcare for low-income people, and education. Thompson earned a BS in 1963 and a JD in 1966 from the University of Wisconsin-Madison.